Mar 1 2010
Merck, the global pharmaceutical and chemical company, announced it is to acquire all outstanding shares of Millipore, the US life sciences company, for US$ 107 per share in cash, or a total transaction value, including net debt, of approximately EUR 5.3 billion (US$ 7.2 billion), creating a world-class partner for the life science sector.
In a video interview on broadcaster http://www.cantos.com, Dr Karl-Ludwig Klay, Merck Chief Executive, said the transaction was "truly transformational" for Merck's Chemicals business.
"We believe that the acquisition is very compelling and fully in line with our strategy."
University of Maine team develops sustainable method to cut drug production costs